Of many viral causes of human cancer, few are of greater global importance than the hepatitis B virus (HBV). Over 250 million people worldwide are persistently infected with HBV. A significant minority of these develop severe pathologic consequences, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Earlier epidemiological evidence suggested a link between chronic HBV infection and HCC. Further, the existence of related animal viruses that induce acute and chronic infections of the liver, and eventually HCC, confirms the concept that HBV belongs to one of the few human oncogenic viruses. Although it is clear that chronic HBV infections are major risk factors, relatively little is understood about how the viral factors contribute to hepatocarcinogenesis. This review will introduce molecular aspects of the viral infection, and highlight recent findings on the viral contribution to hepatocarcinogenesis.
Introduction
In many parts of the world, primary hepatocellular carcinoma (HCC) is one of the most common cancers. In the HBVendemic area, the majority of HCCs arise in patients who are HBV carriers; even though carriers may represent 5%-10% of the population, they represent 50% to 80% of HCC in those countries (Ganem, 1982) . However, stronger evidence for an association comes from careful prospective studies that were done in Taiwan. In this work, large numbers of carriers and non-carriers were followed (Beasley et al., 1981) . These studies demonstrated that chronic HBV carriers are associated with a 100-fold increase in the risk for HCC development relative to noncarriers. This striking number in cancer risk makes HBV one of the most important environmental risk factors in human cancer epidemiology.
Although earlier epidemiological evidence suggested a link between chronic HBV infection and HCC, how the HBV infection leads to hepatocarcinogenesis was not well established (Buendia, 1992) . For many years, studies on viral replication were hampered by a number of experimental limitations. Those limitations were the narrow host range of the virus, which precluded transmission to convenient animal hosts, and the apparent absence of cell lines that supported infection by virus particles. However, progress in understanding the molecular basis of viral replication became possible with the advent of molecular techniques and the discovery of natural animal models of viral infection (Buendia, 1992; Ganem, 1996; Ganem and Varmus, 1987; Nassal, 1996; Nassal and Schaller, 1996) . The purpose of this review is to introduce recent molecular discoveries about the hepadnaviral infection and its long-term consequence to its host, HCC.
Hepadnavirus Genomes
The hepadnaviral genome, isolated from infectious virions, is a partial duplex circular genome whose circularity is maintained by 5' cohesive ends (Fig. 1) . The genome has an unusual structure in that its two DNA strands are not symmetrical. The viral minus-strand is unit length and has a protein that is covalently linked to its 5' end, which is later identified to be P ORF product, the viral polymerase (Bosch et al., 1988; Wang and Seeger, 1992) . By contrast, the plusstrand is less than unit length and bears capped oligoribonucleotides at its 5' end. Importantly, the position of the 5' ends of both strands map to the regions of short (11 nucleotide) direct repeats (DRs) in viral DNA. The 5' end of the minus-strand DNA maps within the repeat (termed DR1), while the plus-strand DNA begins within DR2. As will be *To whom correspondence should be addressed. Tel: 82-2-2123-2708; Fax: 82-2-312-3684 E-mail: wsryu@yonsei.ac.kr discussed later, these repeats serve as a donor or acceptor sites in the template switch events during viral genome synthesis (Ganem and Varmus, 1987; Havert and Loeb, 1997) .
Molecular cloning of HBV DNA that is extracted from Dane particles, infectious virion particles, revealed a coding organization that is highly compact (i.e., every nucleotide in the genome is within a coding region.) As shown in Fig. 1 , 4-open-reading frames (ORF) are present in the genome (Ganem, 1996) . The viral DNA polymerase that is encoded by the P ORF has reverse transcriptase activity. The C (core) ORF encodes the structural protein of the nucleocapsid, while ORF S encodes the viral surface glycoproteins. Lastly, ORF X encodes a viral regulatory protein, HBx, which is best characterized as a transcriptional transactivator (Murakami, 2001) .
Infection Cycle
The peculiar asymmetries of virion DNA provided early clues that a mechanism other than semi-conservative DNA synthesis is involved in the hepadnaviral genome replication. In 1982, Summers and Mason reported a seminal discovery that viral DNA replication proceeds by reverse transcription of an RNA intermediate (Summers and Mason, 1982) . Current understanding of the infection cycle follows. Following receptor binding, virions deliver their nucleocapsids to the cytoplasm. These then translocate to the nucleus, where their genomic DNA is matured to the covalently-closed circular (ccc) DNA form. Then, cccDNA becomes a template for transcription of the pregenomic RNA (pgRNA) and subgenomic RNAs by the host RNA polymerase II. The pgRNA serves as a template for reverse transcription, as well as for the translation of the C and P proteins (Fig. 2 ). Viral pgRNAs are selectively encapsidated within the core particles in the cytoplasm, together with the P gene product (JunkerNiepmann et al., 1990; Hirsch et al., 1991; Jeong et al., 2000) . Within this structure, viral DNA synthesis is initiated; following minus-strand synthesis, plus-strand DNA synthesis occurs. Although they have a DNA genome, hepadnaviruses replicate through reverse transcription of RNA intermediate, resulting in a relaxed circular DNA genome (Summers and Mason, 1982) . Upon completion of genomic DNA synthesis, progeny cores bud into intracellular membranes to acquire their glycoprotein envelope. Enveloped virions are then secreted via the constitutive pathway of the vesicular transport.
Hepadnavirus Family and Animal Models
It is now clear that HBV is one member of a family of related viruses that are now known as hepadnaviruses (for hepatotropic DNA viruses). The first of the nonhuman hepadnaviruses to be discovered was the woodchuck hepatitis virus (WHV). A series of similar viruses have now been discovered from a variety of animal species, including the Pekin duck (duck hepatitis B virus or DHBV) (Ganem and Varmus, 1987) and Beechey ground squirrels (ground squirrel hepatitis virus or GSHV) . The host range of the animal hepadnaviruses is narrow. In most cases, the transmission of virus to hosts that are closely related to the natural host species has been demonstrated. Considerable interest has been paid to WHV. This is because: (i) genome shares approximately a 60% nucleotide sequence identity with its human counterpart, and (ii) all of the WHV carrier woodchucks succumb to HCC after 2-4 years (Popper et al., 1981; Popper et al., 1987) . 
Hepadnaviral Infection and HCC
Besides epidemiological evidence, further support for the oncogenic potential of hepadnavirus infection came with the discovery of the animal hepadnaviruses. In retrospect, animal models of hepadnaviruses, including WHV and GSHV, have been invaluable to further substantiate the link between the HBV infection and HCC (Buendia, 1992) . Studies of the WHV infection showed that this virus is even more potent than HBV as a hepatic carcinogen. Nearly 100% of woodchucks that are infected from birth with WHV will develop HCC, starting at around 18 to 24 months of age (Popper et al., 1981; Popper et al., 1987) . Further, ground squirrels that are infected with GSHV will also display an increased prevalence of HCC, though the tumors are less frequent and arise later in life (Marion et al., 1986 ).
An obvious question that is raised by these observations concerns the role of the virus in liver cancer. The first clue came from the discovery of integrated viral DNA in HCC and HCC-derived cell lines (Brechot et al., 1980; Marion et al., 1980) . The HBV integrants are usually highly rearranged with deletions, inversions, and sequence reiterations that are all commonly observed. In addition, alterations of host DNA often accompany these integrations (Rogler et al., 1985; Yaginuma et al., 1985) . However, unlike retroviruses, chromosomal integration is not an obligatory part of the hepadnaviral infection cycle. Nonetheless, by analogy to the retroviral counterpart, it was speculated that the viral integration might lead to insertional mutagenesis. Importantly, tumors are clonal with respect to these integrants. This implies that the integration event(s) accompanied or preceded the clonal expansion of the cells, which suggests that the viral integration is not the "cause", but the "consequence" (Brechot et al., 2000) .
In contrast, the results that were obtained from the woodchuck model supported the insertional mutagenesis hypothesis. It was found that WHV sequences are present at or near N-myc2, a psuedogene of N-myc, in almost every liver tumor that arose in WHV-infected animals. In almost all of the cases that have been examined, the integration of WHV results in the activation of the transcription of the N-myc2 locus (Fourel et al., 1990; Fourel et al., 1994) . Similar efforts with a tumor that was obtained from HBV-infected patients revealed no common cellular target for HBV integration. Therefore, the insertional mutagenesis that was observed with woodchuck models cannot be generalized beyond the woodchuck models.
Oncogenic Properties of Viral Proteins: HBx
Despite compelling epidemiological evidence, to what extent the viral gene products contribute to hepatocarcinogenesis is still in question. Among the viral gene products, considerable attention was given to HBx (Yen, 1996; Murakami, 2001) . It was noted that three mammalian hepadnaviruses share a regulatory gene (termed X); whereas, no counterpart of this gene is found in the distantly-related nononcogenic duck hepatitis B virus (DHBV) (Ganem and Varmus, 1987) . HBx, a 154 amino acid gene product of the X gene, is known as a promiscuous transcriptional transactivator, since it is capable of transactivating the gene expression by acting on a wide range of viral and cellular regulatory elements (Yen, 1996) . It was, therefore, suggested that HBx might play a role in liver carcinogenesis. Until recently, its role during the infection cycle remained elusive, since HBx has been shown to be dispensable for viral genome replication in tissue cultures (Blum et al., 1992) . Subsequently, the requirement of the HBx gene product for productive viral infection has been firmly established in the woodchuck model (Chen et al., 1993; Zoulim et al., 1994) . Therefore, HBx is an essential viral protein during the viral infection cycle in vivo, although its specific function pertaining to the infection cycle is unknown.
On the other hand, the transcriptional transactivator properties of HBx have been demonstrated on a variety of viral and cellular regulatory elements (Yen, 1996) . HBx does not directly bind to DNA, and may stimulate transcription by interacting with transcription factors or with the basal transcription machinery of host RNA polymerase II and III (Murakami, 2001) . Besides its nuclear function as a transcriptional transactivator, several studies indicated that HBx influences the cellular signaling pathways in the cytoplasm as well, which is a function that is consistent with the predominant cytoplasmic localization of HBx in vivo and in most experimental systems (Benn and Schneider, 1994; Natoli et al., 1994) . Several studies indicated that HBx influences cellular signaling pathways. It was reported that HBx activates src (Klein and Schneider, 1997) and the ras/raf/ ERK pathway, which leads to transcriptional transactivation and the stimulation of proliferation in quiescent cells (Natoli et al., 1994; Benn et al., 1996) . In addition, HBx activates NFkB (Lucito and Schneider, 1992; Chirillo et al., 1996; Su and Schneider, 1996) . Recently, Bouchard et al. reported that HBx enhances HBV replication 5-to 10-fold in transfected HepG2 cells by triggering the cytosolic Ca 2+ release, which in turn activated the proline-rich tyrosine kinase 2 (Pyk2) (Bouchard et al., 2001) . Then, the activated Pyk2 activates Src kinase. They provided compelling evidence that indicated the role of HBx in context of the viral genome replication. It should be interest to identify the vial targets that respond to the Pyk2 and Src activation.
Although the pleiotropic functions of HBx were illustrated, it is unclear which functions directly contribute to the viral carcinogenesis. It is relevant that HBx has been implicated in both the deregulation of the cell cycle control or cell proliferation (Koike et al., 1994b; Benn and Schneider, 1995) , as well as the apoptosis (Chirillo et al., 1997; Kim et al., 1998) . Apoptosis normally eliminates the cells with damaged DNA; that is, the ones that are most likely to engender a neoplastic clone. The proapoptotic activity of HBx may contribute to viral oncogenesis by exerting a selective pressure that favors the emergence of mutated cells. Collectively, HBx has pleiotropic activities that might involve in viral carcinogenesis.
Numerous attempts have been made to examine the oncogenic potential of HBx in cell cultures (Shirakata et al., 1989; Hohne et al., 1990; Oguey et al., 1996; Tarn et al., 1999) . However, its transforming ability was barely measurable, only when the cells were immortalized by other oncogenes, such as the SV40 T-antigen (Hohne et al., 1990) . Further, most of the transgenic mice that harbored the HBx gene had no serious liver diseases or tumors (Koike et al., 1994a; Guidotti et al., 1995) . Only in certain transgenic lineages of the CD-1 strain, where HBx was expressed at high levels, did HBx weakly promote tumorigenesis (Kim et al., 1991) . In addition, HBx was shown to potentate c-myc induced liver oncogenesis in transgenic mice (Terradillos et al., 1997) . Data obtained from these transgenic studies suggested that HBx had no acute transforming activity, but its overexpression in a certain genetic background might induce tumor formation, possibly in collaboration with activated cellular oncogene(s) in the multistage transformation. Although it is generally believed that HBx is a cofactor in hepatocarcinogenesis, there is still no direct evidence for the oncogenic contribution of HBx. Recently, we demonstrated that H-ras collaborates with HBx to transform cells by suppressing the HBx-mediated apoptosis (Kim et al., 2001) . We hypothesized that HBx could contribute to the neoplastic transformation in collaboration with other oncogenes, such as H-ras, that renders cells to counteract the HBx-mediated apoptosis (Fig. 3) . This report not only firmly establishes the oncogenic activity of HBx, but also defines its role during the multistage carcinogenesis.
Perspectives
During the past two decades, the major principles of hepadnavirus infections have been resolved (Seeger and Mason, 2000) . The transfection system that is capable of producing the infectious viral particle has allowed investigators to examine the mechanism of viral genome replication. In addition, the course of viral infections in vivo has been characterized by using animal models. In spite of these accomplishments, many important questions are still unanswered On the level of viral replication, two major issues are still unknown. First, the viral receptor has not been identified. It is generally believed that the viral receptor is a major determinant for the observed tissue tropism of hepadnaviruses. Using the biochemical approach, a novel carboxypeptidase was identified as a potential DHV receptor (Kuroki et al., 1994; Kuroki et al., 1995) . However, the observation that the ectopic expression of the carboxypeptidase did not render cells susceptible to the DHBV infection suggested that additional factors control the viral infection (Tong et al., 1995; Urban et al., 1998) . Secondly, the cis-acting sequences for the viral genome replication are not fully characterized. Although the donor and acceptor sites that are used for the template switches during the hepadnaviral DNA synthesis have been identified (i.e., epsilon, DR1 and DR2), it is largely unknown whether other cis-acting sequences (apart from the donor and acceptor sites) might be involved in the template switches during the hepadnaviral DNA synthesis. Recently, three additional cisacting elements (named 3E, M, and 5E) were identified in DHBV, which when deleted, abrogates the plus-strand DNA synthesis (Havert and Loeb, 1997) . In contrast, it is unknown whether such cis-acting elements exist for HBV genome replication. Complete mapping of the cis-acting element will facilitate in designing a novel HBV-derived liver-targeting vector. Such recombinant viral vectors have been essential for the unambiguous identification of retroviral receptors, including those of the Moloney murine leukemia virus, avail leukosis virus, and human immunodeficiency virus (Dalgleish et al., 1984; Albritton et al., 1989; Young et al., 1993) . Further, the HBV vector will be a novel hepatotropic gene therapy vector to treat genetic disease, as well as liver diseases (Protzer et al., 1999) .
Regarding viral carcinogenesis, the specific contribution of HBx to oncogenesis is still largely unknown. Recent evidence for HBx's role in triggering the cytosolic Ca 2+ release needs to be further explored in context to oncogenesis as follows (Bouchard et al., 2001 ): (i) By what mechanism does HBx trigger the Ca 2+ release? (ii) What are the consequences of the Ca 2+ release to the host cell? In addition, the genetic dissection of the HBx polypeptide will take us one step closer to closure of the X files (Ganem, 2001; Nassal, 2002) . A molecular analysis of these unresolved issues should provide insights into which new therapeutic targets could be identified to cure the enormous number of patients with chronic HBV infections.
